8-(叔丁氧基羰基氨基)-5,6,7,8-四氢萘-2-羧酸 | 130532-76-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 8-(叔丁氧基羰基氨基)-5,6,7,8-四氢萘-2-羧酸
• 英文名称: (RS)-8-<(tert-Butoxy)carbonylamino>-5,6,7,8-tetrahydronaphtho-2-oic Acid
• 英文别名: 8-((tert-Butoxycarbonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid；8-[(2-methylpropan-2-yl)oxycarbonylamino]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
• CAS: 130532-76-2
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: PSEAKRBXZOBNFR-UHFFFAOYSA-N

物化性质

• 熔点：
  209-210.5 °C
• 沸点：
  460.0±44.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  8-(叔丁氧基羰基氨基)-5,6,7,8-四氢萘-2-羧酸 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa

  摘要：

  Although peptides adopt a large ensemble of conformations in aqueous solution, they are generally believed to bind to a receptor in a unique conformation. Thus, there is considerable interest in devising methods to restrict the conformational freedom of peptides. One such approach involves tying the amino and carboxy terminal ends of the peptide onto a semirigid template that will lock the intervening peptide backbone into a single conformer or a family of related conformers. This general strategy has been tested using the tripeptide sequence Arg-Gly-Asp (RGD), which binds with low affinity to the platelet glycoprotein IIb/IIIa (GPIIb/IIIa or alpha(IIb)beta(3)) Mimics of RGD are of interest as antithrombotics because of their ability to inhibit the aggregation of platelets. Prior to this study, other workers (Samanen et al. J. Med. Chem. 1991, 34, 3114-3125) prepared a disulfide-containing cyclic pentapeptide that bound to GPIIb/IIIa with an affinity of approximately 0.1 mu M. NMR analysis of the solution conformation of this peptide suggested that replacing the disulfide-containing portion of the cycle with the amino acid m-(aminomethyl)benzoic acid would lead to a more rigid structure. Indeed, introduction of this template into a cyclic ROD-containing peptide resulted in compounds with high affinity for the receptor. Further, systematic inclusion of additional conformational constraints in the form of N-alpha- and C-alpha-alkyl groups led to a peptide with an affinity of approximately 100 pM for binding to the receptor. This peptide also showed good activity in the platelet aggregation assay at oral doses as low as 0.1 mg/kg.

  DOI：

  10.1021/ja00087a007
• 作为产物：
  描述：

  8-氧代-5,6,7,8-四氢萘-2-羧酸 在 palladium on activated charcoal 氢气 、 羟胺 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 25.0~60.0 ℃ 、399.99 kPa 条件下， 反应 7.0h， 生成 8-(叔丁氧基羰基氨基)-5,6,7,8-四氢萘-2-羧酸
  参考文献：
  名称：

  模板组装的合成蛋白（TASP）。结合了旋转诱导模拟物的循环模板

  摘要：

  8-氨基-5,6,7,8-四氢萘-2-酸（1），8-（氨基甲基）-5,6,7,8-四氢萘-2-油酸（2）和8- （氨基甲基）萘-2-油酸（3）以其被保护的形式合成为诱导转弯的二肽模拟物。它们（两个2和3）被纳入了一种新型环状，基于肽的结构（见21和34 - 36）设计为用于TASP分子的合成模板。

  DOI：

  10.1002/hlca.19930760414

文献信息

• Substituted Benzamide Compounds
  申请人：Reich Melanie

  公开号：US20120071461A1

  公开（公告）日：2012-03-22

  Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

  对应于式(I)的取代苯甲酰胺化合物，其中R5、R6、R7、R8、a、b、c、d、t、D和X具有定义的含义，其制备方法，包括这些化合物的药物组合物，以及使用这些化合物治疗疼痛和其他至少部分通过激肽酶1受体介导的疾病的方法。
• [DE] SUBSTITUIERTE BENZAMID-VERBINDUNGEN<br/>[EN] SUBSTITUTED BENZAMIDE COMPOUNDS<br/>[FR] COMPOSÉS DE BENZAMIDE SUBSTITUÉS
  申请人：GRUENENTHAL GMBH

  公开号：WO2012038081A1

  公开（公告）日：2012-03-29

  Die vorliegende Erfindung betrifft substituierte Benzamid-Verbindungen, Verfahren zu deren Herstellung, Arzneimittel enthaltend diese Verbindungen und die Verwendung von substituierten Benzamid-Verbindungen zur Herstellung von Arzneimitteln. Die Verbindungen sind nützlich als B1R -Modulatoren zur Behandlung von z.B. Schmerz.

  本发明涉及取代苯甲酰胺化合物，其制备方法，含有这些化合物的药物以及使用取代苯甲酰胺化合物制备药物。这些化合物在治疗疼痛等方面是有用的B1R调节剂。
• ERNEST, I.;KALVODA, J.;RIHS, G.;MUTTER, M., TETRAHEDRON LETT., 31,(1990) N8, C. 4011-4014
  作者：ERNEST, I.、KALVODA, J.、RIHS, G.、MUTTER, M.

  DOI：——

  日期：——
• US8680159B2
  申请人：——

  公开号：US8680159B2

  公开（公告）日：2014-03-25
• Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa
  作者：Sharon Jackson、W. DeGrado、A. Dwivedi、A. Parthasarathy、A. Higley、J. Krywko、A. Rockwell、J. Markwalder、G. Wells

  DOI：10.1021/ja00087a007

  日期：1994.4

  Although peptides adopt a large ensemble of conformations in aqueous solution, they are generally believed to bind to a receptor in a unique conformation. Thus, there is considerable interest in devising methods to restrict the conformational freedom of peptides. One such approach involves tying the amino and carboxy terminal ends of the peptide onto a semirigid template that will lock the intervening peptide backbone into a single conformer or a family of related conformers. This general strategy has been tested using the tripeptide sequence Arg-Gly-Asp (RGD), which binds with low affinity to the platelet glycoprotein IIb/IIIa (GPIIb/IIIa or alpha(IIb)beta(3)) Mimics of RGD are of interest as antithrombotics because of their ability to inhibit the aggregation of platelets. Prior to this study, other workers (Samanen et al. J. Med. Chem. 1991, 34, 3114-3125) prepared a disulfide-containing cyclic pentapeptide that bound to GPIIb/IIIa with an affinity of approximately 0.1 mu M. NMR analysis of the solution conformation of this peptide suggested that replacing the disulfide-containing portion of the cycle with the amino acid m-(aminomethyl)benzoic acid would lead to a more rigid structure. Indeed, introduction of this template into a cyclic ROD-containing peptide resulted in compounds with high affinity for the receptor. Further, systematic inclusion of additional conformational constraints in the form of N-alpha- and C-alpha-alkyl groups led to a peptide with an affinity of approximately 100 pM for binding to the receptor. This peptide also showed good activity in the platelet aggregation assay at oral doses as low as 0.1 mg/kg.